Why Im Not Arbing The Fresenius Akorn Deal | Latest News RSS feed

Why Im Not Arbing The Fresenius Akorn Deal - Latest News


Why I'm Not Arbing The Fresenius / Akorn Deal

I am not interested in risk-arbing this deal at the current risk/reward profile (6.25% in 1 year). The deal continues to make sense from a strategic perspective for Fresenius, but I think Akorn has si... read more

Corruption Currents: Trump Asserts ‘Absolute Immunity’ in Emoluments Lawsuit

(AM ... if she is not indicted on charges of misusing government funds. (Haaretz) Court documents made public this week show Germany-based healthcare company Fresenius Medical Care & Co. said it found ... read more

Fresenius says will not renegotiate after cancelling Akorn deal

FRANKFURT, April 23 (Reuters) - Fresenius ... not be ruled out entirely. "The announcement will create speculation about whether this really is the end of the deal, or simply an opening salvo, albeit ... read more

Looking for another news?


Akorn was warned about problems that scotched $4.3B Fresenius deal, exec testifies

Fresenius officials contend manufacturing problems at the Decatur plant and others, along with Akorn's submission of allegedly phony data to federal regulators, are justifications for nixing the $34-p... read more


Can Akorn Win Its Fight Against Fresenius?

Akorn Inc. (NASDAQ: AKRX) shares were crushed on Monday (although not as bad as at Prothena ... but who will win is still yet to be seen. Fresenius said Sunday it would terminate the $4.3 billion deal ... read more

Akorn, Inc: Business Is In Distress

If the company manages to force Fresenius to acquire it, fine, otherwise buying this stock is a speculation the company has another big hit up its sleeve. Akorn ... are why I am not enthusiastic ... read more

Akorn To Appeal Court Ruling In Complaint Against Fresenius Kabi - Quick Facts

(RTTNews) - Akorn, Inc. (AKRX) issued a statement in response to the ruling by the Delaware Chancery Court on the complaint filed by the company against Fresenius Kabi AG. The company stated that it i... read more

Five at 5: Akorn fighting back as European company retreats from takeover and 4 other stories to see

Akorn ... deal, citing alleged breaches of data integrity requirements. But Akorn, which has two facilities and more than 300 employees in Decatur, is fighting back. The generic drug maker today asked ... read more

Why Akorn Shares Were Halved

Delaware’s Vice Chancellor Travis Laster noted that Fresenius validly terminated the merger agreement and he found Akorn’s representations regarding its compliance with regulatory requirements were “n... read more

Why Diana Shipping, Akorn, and Granite Construction Jumped Today

But if JPMorgan is right, then a greater level of confidence in the shipping industry could lead to further gains not just for ... Already, Fresenius has made some strategic purchases within Europe, b... read more

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

Berenberg analyst Tom Jones said the price tag of 12.4 times Akorn's core earnings (adjusted EBITDA) estimate for 2017 should not "give ... GMT (3.50 am ET), broadly in line with the European healthca... read more

Akorn Issues Statement on Investigation

... found any facts that would result in a material impact on Akorn’s operations and the Company does not believe this investigation should affect the closing of the transaction with Fresenius. The Co... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us